-
-
公开(公告)号：KR1020170080503A
公开(公告)日：2017-07-10
申请号：KR1020160181279
申请日：2016-12-28
Applicant: (주)아모레퍼시픽 , 가부시기가이샤후시미세이야꾸쇼
Abstract: 본명세서에는항균물질을포함함으로써세균과곰팡이에대해서항균력을가지고, 안정한내구성과발포물성을갖는화장료조성물도포구가개시된다. 본발명은안전하게밀폐용기에내장이가능하며, 고온다습한지역의사용자들이안심하고사용할수 있는화장료조성물도포구를제공할수 있다.
Abstract translation: 在本说明书中，还公开了具有抗细菌和真菌的抗微生物活性并且具有稳定的耐久性和泡沫性质的化妆品组合物。 本发明可以安全地安装在密封容器中，并且用户可以在炎热和潮湿的区域安全使用的化妆品组合物也可以提供端口。
-
-
公开(公告)号：KR1020140069930A
公开(公告)日：2014-06-10
申请号：KR1020120137821
申请日：2012-11-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K8/0212 , A61K8/042 , A61K8/42 , A61K8/64 , A61Q19/00
Abstract: The present invention provides a silk hydrogel composition containing 0.01-30 wt% of a silk fibroin powder and 0.01-10 wt% of urea, and a method for manufacturing a silk hydrogel mask using the same. According to the present invention, the solubility of silk fibroin in a raw material is increased and the silk fibroin is gelled for a short period of time, thereby allowing a continuous process, and the silk hydrogel can be packaged immediately after being cut, thereby requiring no additional process and thus improving production safety and efficiency. Further, the silk hydrogel composition according to the present invention can control the moisture release rate while exhibiting excellent hardness and adhesive strength, reduce irritation as it is a silk material having high affinity with the human body, and be effective in maintaining the moisture content and the moisturizing capability, removing dead skin cells, brightening, and reducing redness, and thus can be used in a cosmetic mask.
Abstract translation: 本发明提供含有0.01-30重量％丝素蛋白粉末和0.01-10重量％尿素的丝素水凝胶组合物，以及使用其制造丝素水凝胶掩模的方法。 根据本发明，丝素蛋白在原料中的溶解度增加，丝素蛋白凝胶化短时间，从而可以进行连续处理，丝状水凝胶可以在切割后立即包装，从而要求 没有额外的过程，从而提高生产安全性和效率。 此外，根据本发明的丝状水凝胶组合物可以控制水分释放速度，同时显示出优异的硬度和粘合强度，减少作为与人体具有高亲和力的丝素材料的刺激性，并且有效地保持水分含量， 保湿功能，去除死皮细胞，增亮，减少发红，因此可用于化妆品面膜。
-
公开(公告)号：KR1020140035133A
公开(公告)日：2014-03-21
申请号：KR1020120101606
申请日：2012-09-13
Applicant: (주)아모레퍼시픽
Abstract: An electroporation device according to an embodiment of the present invention comprises: multiple electrode pins touching skin to perforate the skin; a wiring board having a wiring pattern to transmit voltage to the multiple electrode pins; a voltage generating part generating the voltage transmitted to the multiple electrode pins through the wiring pattern of the wiring board; a controlling part controlling the polarity of the voltage transmitted to the multiple electrode pins to make any neighboring electrode pins among the multiple electrode pins have different polarities in every cycle; and a voltage compensating part measuring the resistance of the skin where the multiple electrode pins touch, and compensating the voltage level transmitted to the multiple electrode pins according to the resistance level. [Reference numerals] (110) Main body; (111) Power unit; (112) Voltage generating part; (113) Controlling part; (114) Operation display part; (115) Power display part; (116) Voltage compensating part; (120) Perforating part; (121) Wiring board; (122) Electrode pin; (123) Pin guide; (130) Piezo switch
Abstract translation: 根据本发明的实施例的电穿孔装置包括：多个电极针接触皮肤以穿透皮肤; 具有向多个电极引脚传输电压的布线图案的布线板; 电压产生部件，通过布线板的布线图形产生传输到多个电极引脚的电压; 控制部分控制传输到多个电极引脚的电压的极性，使得多个电极引脚中的任何相邻的电极引脚在每个周期中具有不同的极性; 以及电压补偿部，其测量多个电极引脚接触的皮肤的电阻，并根据电阻水平补偿传输到多个电极引脚的电压电平。 （附图标记）（110）主体; （111）动力单元; （112）电压产生部; （113）控制部分; （114）操作显示部分; （115）电源显示部分; （116）电压补偿部; （120）穿孔部分; （121）接线板; （122）电极针; （123）引脚引导; （130）压电开关
-
Patent Agency Ranking
公开(公告)号：KR1020140012336A
公开(公告)日：2014-02-03
申请号：KR1020120078921
申请日：2012-07-19
Applicant: (주)아모레퍼시픽
CPC classification number: A61M5/3298 , A61M5/20 , A61M5/204 , A61M5/2053 , A61M5/30 , A61M5/31511 , A61M5/46 , A61M37/0015 , A61M2037/0023 , A61M2037/003
Abstract: The present invention relates to a nozzle device and a minimal invasive injection device comprising the same. The nozzle device for the minimal invasive injection device by an embodiment of the present invention includes: an outlet forming a liquid microjet; and a microsized inlet connected to the outlet to be inserted into the skin tissue to a predetermined depth.
Abstract translation: 本发明涉及喷嘴装置和包括该喷嘴装置的最小侵入注射装置。 本发明的一个实施例的用于最小侵入式注射装置的喷嘴装置包括：形成液体微喷嘴的出口; 以及连接到出口的微型入口以插入皮肤组织到预定深度。
-
67.发明公开난용성 약물의 나노입자를 포함하는 분말의 제조방법, 그에의해 제조된 분말 및 이를 포함하는 약학적 조성물 无效制备包含可溶性药物纳米颗粒的粉末的方法，由相同方法制备的粉末和包含相同粉末的药物组合物
公开(公告)号：KR1020100052262A
公开(公告)日：2010-05-19
申请号：KR1020080111205
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A method for manufacturing powder containing nanoparticles of insoluble drug is provided to maintain nanoscopic insoluble drug and enhance elusion rate and solubility of drug. CONSTITUTION: A method for manufacturing powder containing nanoparticles of insoluble drug comprises: a step of preparing homogenized dispersion solution of insoluble drug under the presence of surface stabilizer; a step of mixing homogenized dispersion agent and water soluble dispersion solution; and a step of drying mixture solution and collecting powder. The water soluble dispersion agent is gelatin, carrageenan, alginic acid, arabinoxylan, beta-glucan, guar gum, locust soybean gum, pectin, starch, casein, glucomannan, cyclodextrin, methylcellulose, chitosan, or gluten. A pharmaceutical composition contains powder containing nanoparticles of insoluble drug and pharmaceutically acceptable carrier.
Abstract translation: 目的：提供一种制造含有不溶性药物纳米颗粒的粉末的方法，以维持纳米级不溶性药物，提高药物的洗脱速度和溶解度。 构成：制造含有不溶性药物的纳米颗粒的粉末的方法，包括：在表面稳定剂的存在下制备均质的不溶性药物分散液的步骤; 混合均匀分散剂和水溶性分散液的步骤; 以及干燥混合溶液并收集粉末的步骤。 水溶性分散剂为明胶，角叉菜胶，藻酸，阿拉伯木聚糖，β-葡聚糖，瓜尔胶，槐豆胶，果胶，淀粉，酪蛋白，葡甘露聚糖，环糊精，甲基纤维素，壳聚糖或麸质。 药物组合物包含含有不溶性药物和药学上可接受的载体的纳米颗粒的粉末。
-
公开(公告)号：KR1020080076382A
公开(公告)日：2008-08-20
申请号：KR1020070016221
申请日：2007-02-15
IPC: A61K9/22 , A61K31/4709
CPC classification number: A61K9/0065 , A61K9/2031 , A61K9/2054 , A61K31/4709
Abstract: A controlled-release preparation containing cilostazol is provided to improve absorption rate of cilostazol in small intestine and reduce side effects such as headache by staying in stomach for a long time and slowly releasing cilostazol, and enhance compliance of patient by reducing dosage frequency. A controlled-release preparation contains 10-80 wt.% of cilostazol or its pharmaceutically acceptable salt, 0.1-50 wt.% of solubilizer, 5-80 wt.% of swelling agent, 0.5-50 wt.% of swelling speed-controller and 0.1-50 wt.% of gas-generating material. A method for preparing the controlled-release preparation containing cilostazol comprises the steps of: mixing cilostazol or its pharmaceutically acceptable salt, solubilizer, swelling agent, swelling speed-controller and gas-generating material; granulating the mixture; and filling the granulates in capsules or tabletting the granulates.
Abstract translation: 提供含有西洛他唑的控释制剂，以提高西洛他唑在小肠中的吸收率，并通过长时间停留在胃中并缓慢释放西洛他唑，减少头痛的副作用，并通过降低剂量频率增强患者的依从性。 控释制剂含有10-80重量％的西洛他唑或其药学上可接受的盐，0.1-50重量％的增溶剂，5-80重量％的溶胀剂，0.5-50重量％的溶胀速度控制剂 和0.1-50重量％的气体发生材料。 制备含有西洛他唑的控释制剂的方法包括以下步骤：将西洛他唑或其药学上可接受的盐，增溶剂，溶胀剂，溶胀速度控制器和产气材料混合; 制粒混合物; 并将颗粒填充在胶囊中或压制颗粒。
-
公开(公告)号：KR1020050039573A
公开(公告)日：2005-04-29
申请号：KR1020040083363
申请日：2004-10-19
Applicant: (주)아모레퍼시픽
IPC: C07C335/12
CPC classification number: C07C335/12 , A61K31/17 , A61K31/255
Abstract: 본 발명은, 바닐로이드 수용체(Vanilloid Receptor1, VR1)에 대한 뛰어난 길항작용을 가지고 있으나 물에 난용성인 티오우레아 유도체 또는 약제학적으로 허용가능한 그의 염, 시클로덱스트린 또는 그의 유도체, 그리고, 임의적으로, 약제학적으로 허용되는 첨가제를 포함하는 약제학적 조성물에 관한 것이다.
본 발명의 약제학적 조성물은 티오우레아 유도체의 용해도 및 용출율이 크게 개선되어 매우 우수한 생체내이용률을 나타내었다. 따라서 바닐로이드 수용체에 대한 뛰어난 길항작용을 가지고 있는 티오우레아 유도체의 다양하고 효과적인 투여용 제제화가 가능하게 되었으며 이에 상기 화합물의 인체에 대한 적용이 더욱 현실적으로 실현가능하게 되어 그 유용성이 크게 기대된다.-
公开(公告)号：KR1020040067969A
公开(公告)日：2004-07-30
申请号：KR1020040003871
申请日：2004-01-19
Applicant: (주)아모레퍼시픽
IPC: A61K9/16
CPC classification number: A61K9/2077 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2095 , A61K9/2846 , A61K9/2866 , A61K31/00 , A61K31/485
Abstract: PURPOSE: Provided is a controlled release preparation which minimizes the addition of a hydrophobic material, and prevents the surface adhesion of granules. The controlled release preparation continuously releases the drug content for 12 hours while maintaining the effective drug concentration in blood. CONSTITUTION: The controlled release preparation comprises 0.5-80wt.% of drug, 10-65wt.% of a hydrophobic release control additive, and 1-35wt.% of a hydrophobic wet granulating material. The drug is first melt-granulated using the hydrophobic release control additive, and the resulting granules are second wet-granulated using the hydrophobic wet granulating material.
Abstract translation: 目的：提供一种控制释放制剂，其最小化添加疏水性材料，并防止颗粒的表面粘附。 控释制剂连续释放药物含量12小时，同时保持血液中有效的药物浓度。 构成：控释制剂包含0.5-80重量％的药物，10-65重量％的疏水释放控制添加剂和1-35重量％的疏水湿法制粒材料。 首先使用疏水性释放控制添加剂对药物进行熔融造粒，并使用疏水性湿法制粒材料将得到的颗粒进行第二次湿法造粒。
-
-
-
-
-
-
-
-
-
Search Results
70
records
(took 0.031 seconds)
